Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
Teva Releases Q1 2025 Aide Memoire
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
You are about to leave the Teva Pharmaceuticals global website
The website you are about to access may be governed by different regional policies, regulations or advertising codes. Please be sure to read the privacy policy and terms of use of the websites that you visit.
Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws of information on any third party websites.
